{"entity":{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","aka":[],"tldr":"Priyanka Sharma is a TNBC trialist testing whether anthracyclines can be dropped from pre-surgery treatment.","summary":"Priyanka Sharma is Professor of Medicine at The University of Kansas Cancer Center and Study Chair of SWOG S2212 (SCARLET) within the SWOG Cancer Research Network. A breast medical oncologist specialising in triple-negative breast cancer, platinum chemotherapy and de-escalation trials, she led NeoSTOP and now leads SCARLET, which compares anthracycline-free carboplatin and docetaxel plus pembrolizumab with the KEYNOTE-522 regimen, testing whether anthracyclines can be dropped from pre-surgery treatment. Her papers report the NeoSTOP randomised phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens in triple-negative breast cancer and a combined two-cohort analysis of neoadjuvant carboplatin plus docetaxel in the same disease.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Priyanka%20Sharma"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","pembrolizumab"],"companies":["swog"],"institutions":["ku-cancer-center"],"pathways":[],"terms":[],"trials":["scarlet-s2212"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, University of Kansas Cancer Center; Study Chair, SWOG S2212 (SCARLET)","institutionId":"swog","specialisms":["Triple-negative breast cancer","Platinum chemotherapy","De-escalation trials"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Priyanka%20Sharma"}],"papers":[{"title":"Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)","journal":"Clinical Cancer Research","year":2021,"url":"https://doi.org/10.1158/1078-0432.CCR-20-3646","doi":"10.1158/1078-0432.CCR-20-3646"},{"title":"Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts","journal":"Clinical Cancer Research","year":2017,"url":"https://doi.org/10.1158/1078-0432.CCR-16-0162","doi":"10.1158/1078-0432.CCR-16-0162"}]},"route":"/people/priyanka-sharma/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"institution":[{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/"}],"trial":[{"id":"scarlet-s2212","kind":"trial","name":"SCARLET (SWOG S2212)","route":"/trials/scarlet-s2212/"}],"paper":[{"id":"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","kind":"paper","name":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","route":"/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/"},{"id":"paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023","kind":"paper","name":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease","route":"/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/"},{"id":"paper-sharma-tnbc-registry-germline-brca-bcrt-2014","kind":"paper","name":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing","route":"/key-papers/paper-sharma-tnbc-registry-germline-brca-bcrt-2014/"},{"id":"paper-couch-tnbc-germline-17-genes-jco-2015","kind":"paper","name":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","route":"/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/"}]}}